Published On: Fri, Dec 1st, 2023

Pfizer to stop developing its twice-daily weight loss pill due to adverse side effects

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies.
Daily Express :: Health Feed

About the Author

-

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Pfizer to stop developing its twice-daily weight loss pill due to adverse side effects